EGFR and non-small cell lung carcinoma: Available data from completed phase 3 trials of EGFR or ErbB family TKIs in EGFR mutation-positive NSCLC or clinically selected populations are summarized in Tables1 and 2 and discussed below, along with recent phase 2 data for the newer generation of irreversible agents.